<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01670149</url>
  </required_header>
  <id_info>
    <org_study_id>12072</org_study_id>
    <secondary_id>2012-003205-10</secondary_id>
    <nct_id>NCT01670149</nct_id>
  </id_info>
  <brief_title>Rifaximin for Preventing Relapse of Clostridium Associated Diarrhoea</brief_title>
  <acronym>RAPID</acronym>
  <official_title>A Randomised Placebo Controlled Trial of &quot;Follow on&quot; Rifaximin for the Prevention of Relapse of Clostridium Associated Diarrhoea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nottingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute for Health Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Nottingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clostridium difficile associated diarrhoea is an important cause of morbidity in patients&#xD;
      treated with antibiotics, especially in hospital. Clinical relapse occurs after up to 30% of&#xD;
      initially successful treatments for colitis. Preliminary reports suggest that Rifaximin, a&#xD;
      poorly absorbed antibiotic used to treat travellers diarrhoea can prevent relapse. We plan to&#xD;
      carry out a randomised placebo controlled trial to test the hypothesis that Rifaximin given&#xD;
      in a reducing dose over 4 weeks after successful treatment will reduce the relapse rate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aims i) To examine efficacy of a follow-on course of Rifaximin given after a successful&#xD;
      initial course of standard treatment, in the prevention of relapse in C. difficile associated&#xD;
      diarrhoea (CDAD).&#xD;
&#xD;
      ii) To examine changes in faecal microbiota in patients given Rifaximin vs. Placebo.&#xD;
&#xD;
      Treatment 4 weeks treatment with Rifaximin or Placebo tablets. Tapering dose starting with 2&#xD;
      x 200mg tablets three times a day (total = 1.2g per day) for the 1st 2 weeks, reduced to 1 x&#xD;
      200mg tablet three times a day (total = 0.6g per day) for the 2nd 2 weeks.&#xD;
&#xD;
      Primary endpoint: The difference in % relapse between Rifaximin and placebo at 12 weeks&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in % relapse between Rifaximin and placebo at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>The difference in % relapse between Rifaximin and placebo at 12 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion relapsed, re-hospitalisation and bowel symptoms</measure>
    <time_frame>12 weeks - 6 months</time_frame>
    <description>Secondary endpoints:&#xD;
Clinical:&#xD;
Proportion with relapse of CDAD within 6 months&#xD;
Proportion re-hospitalised for CDAD within 6 months&#xD;
Length of in-hospital stay following start of treatment&#xD;
Exploratory:&#xD;
Stool frequency and consistency during 12 weeks after start of treatment&#xD;
Microbiological assessments</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">151</enrollment>
  <condition>Clostridium Difficile Infection</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identical looking tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rifaximin , Xifaxanta™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 weeks of Rifaximin 400mg thrice daily then 2 weeks of Rifaximin 200mg thrice daily Modified Xifaxanta™ (rifaximin film-coated tablet) manufactured by Alfa Wasermann (AW),</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>Tablets</description>
    <arm_group_label>Rifaximin , Xifaxanta™</arm_group_label>
    <other_name>Xifaxanta™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Men / Women aged 18 and over (We will also include those adults who lack mental&#xD;
             capacity for whom we have a legal representative)&#xD;
&#xD;
          2. Successful treatment of clinically diagnosed CDAD using standard therapy&#xD;
             (metronidazole or vancomycin given according to standard local hospital guidelines).&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Woman of child bearing potential and not willing to use at least one highly effective&#xD;
             contraceptive method throughout the study&#xD;
&#xD;
          2. Male with spouse/partner of child bearing potential and not willing to use condoms&#xD;
&#xD;
          3. Pregnant or breast feeding&#xD;
&#xD;
          4. Unable to swallow tablets&#xD;
&#xD;
          5. Life expectancy of &lt;4 weeks&#xD;
&#xD;
          6. Hypersensitivity to the active substance, to any rifamycin (e.g. rifampicin or&#xD;
             rifabutin) or to any of its excipients (Tablet core: Sodium starch glycolate type A,&#xD;
             glycerol distearate, colloidal anhydrous, silica, talc and microcrystalline cellulose.&#xD;
             Tablet coating: hypromellose, titanium dioxide (E171), disodium edentate, propylene&#xD;
             glycol and red iron oxide E172)&#xD;
&#xD;
          7. &gt;5 days post standard therapy (metronidazole or vancomycin) for clinically diagnosed&#xD;
             CDAD&#xD;
&#xD;
          8. Taking ciclosporin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aida Jawhari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nottingham University Hospitals NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nottingham Clinical Trials Unit (NCTU), Queen's Medical Centre</name>
      <address>
        <city>Nottingham</city>
        <state>Nottinghamshire</state>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-003205-10/results</url>
    <description>Summary results EU Clinical Trials Register</description>
  </link>
  <results_reference>
    <citation>Major G, Bradshaw L, Boota N, Sprange K, Diggle M, Montgomery A, Jawhari A, Spiller RC; RAPID Collaboration Group. Follow-on RifAximin for the Prevention of recurrence following standard treatment of Infection with Clostridium Difficile (RAPID): a randomised placebo controlled trial. Gut. 2019 Jul;68(7):1224-1231. doi: 10.1136/gutjnl-2018-316794. Epub 2018 Sep 25.</citation>
    <PMID>30254135</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 17, 2012</study_first_submitted>
  <study_first_submitted_qc>August 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2012</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clostridium difficile</keyword>
  <keyword>Diarrhoea</keyword>
  <keyword>Rifaximin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clostridium Infections</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

